We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Meritage Homes, Sarepta Therapeutics, The Clorox Company, The Hain Celestial Group and Entergy
Read MoreHide Full Article
For Immediate Release
Chicago, IL – April 15, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Meritage Homes Corp. (MTH - Free Report) , Sarepta Therapeutics, Inc. (SRPT - Free Report) , The Clorox Company (CLX - Free Report) , The Hain Celestial Group, Inc. (HAIN - Free Report) and Entergy Corp. (ETR - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
5 Stocks to Win Big This Brutal Q1 Earnings Season
First-quarter corporate profits will certainly show contraction as the economy is hammered by the coronavirus outbreak and the subsequent shutdowns. The quarter will most likely be a complete washout for many companies, particularly retailers and restaurants.
The pandemic has also brought Airline, Hospitality and Auto industries to a grinding halt. These segments have been hurt by the massive drop in discretionary spending.
Overall, business activities in the United States contracted in March, slipping to a record low as the outbreak dampened activity in the manufacturing and service sectors. The virus, in particular, has crippled the manufacturing sector primarily due to the stay-at-home directives in several parts of the country. Coronavirus-induced supply chain disruptions and social distancing measures impacted factory activities.
By the way, earnings estimates for the first quarter have started to move down as the pandemic has halted economic growth and led market pundits to forecast a recession this year. Several oil bigwigs including Exxon Mobil and Chevron have slashed estimates. After all, the pandemic has hit oil demand and led to oversupply issues.
Automakers General Motors and Ford, and aerospace giant Boeing too trimmed estimates. In fact, Bank of America sees first-quarter earnings decline of 13% year over year. It also expects year-on-year earnings decline in all four quarters of this year, marking the first recession since 2015-16.
Broader bank earnings are going to take a hit as well. A low interest rate environment does cut into net interest income for banks. At the same time, rising unemployment is expected to result in increased loan losses, something that will weigh on banks’ earnings. Companies had to lay off workers in the wake of the rapid spread of COVID-19 and its impact on businesses (read more: 4 Winning Bank Stocks for Coronavirus-Marred Q1 Earnings).
For the first quarter as a whole, total earnings for S&P 500 companies are expected to drop 9% from the same period last year. Revenues, in the meanwhile, are likely to rise only 1.6% (read more: What to Expect from Big Bank Earnings Amid the Coronavirus?).
On the brighter side, there are certain sectors which might see earnings growth. Such sectors with positive earnings growth in the first quarter includes Construction (+4.2%), Medical (+0.9%), Consumer Staples (+0.6%) and Utilities (+1.9%). The virus scare has fueled demand for U.S. debt, which in turn pushed Treasury yields to new lows. Mortgage rates are most likely to go down as they generally follow the direction of the yield on the 10-year Treasury note in the United States. And lower mortgage rates will certainly boost homebuying.
Medical stocks have also defied the turbulent times. And it’s mostly because these companies are trying to develop a treatment for coronavirus, which helped garner impressive gains over the last couple of weeks. And should these clinical tests prove successful, such stocks will scale north.
And as the market is plagued with uncertainty, defensive stocks have performed relatively better. This is because such stocks are generally non-cyclical, or companies whose business performance and sales are not highly correlated with activities in the larger market. Their products are in constant demand irrespective of market volatility and such companies include names from the utilities and consumer staples sectors.
Utilities are deemed defensive stocks as electricity, gas and water are essentials. Food, beverage and tobacco companies are true defensive plays as demand for such staple stocks remains unaffected by economic downturns.
5 Stocks to Gain Heading Into Q1 Earnings
It will be prudent to consider solid companies from the aforesaid winning sectors, which are expected to report an uptick in first-quarter earnings. These stocks have a positive Earnings ESP. This is our proprietary methodology for determining stocks that have the best chance to surprise with their next earnings announcement. It provides the percentage difference between the Most Accurate Estimate and the Zacks Consensus Estimate.
Meritage Homes Corp. is one of the leading designers and builders of single-family homes. The stock has a Zacks Rank #3 (Hold). The company is expected to report earnings results for the quarter ending March on Apr 28. Meritage Homes has an Earnings ESP of +4.70%. The company’s expected earnings growth rate for the current quarter and year is 25.2% and 6.4%, respectively.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The stock has a Zacks Rank #3. The company is expected to report earnings results for the quarter ending March on May 13. Sarepta Therapeutics has an Earnings ESP of +20.20%. The company’s expected earnings growth rate for the current quarter is 48.1%.
The Clorox Company manufactures and markets consumer and professional products. The stock has a Zacks Rank #1 (Strong Buy). The company is expected to report earnings results for the quarter ending March on May 1. Clorox has an Earnings ESP of +1.81%. The company’s expected earnings growth rate for the current and next year is 1.7% and 5.4%, respectively. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Hain Celestial Group, Inc. manufactures, markets, distributes, and sells organic and natural products. The stock has a Zacks Rank #1. The company is expected to report earnings results for the quarter ending March on May 14. Hain Celestial has an Earnings ESP of +9.24%. The company’s expected earnings growth rate for the current quarter and year is 14.3% and 10.6%, respectively.
Entergy Corp. engages in the production and distribution of electricity in the United States. The stock has a Zacks Rank #3. The company is expected to report earnings results for the quarter ending March on May 6. Entergy has an Earnings ESP of +5.69%. The company’s expected earnings growth rate for the current and next year is 2.8% and 7.9%, respectively.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Meritage Homes, Sarepta Therapeutics, The Clorox Company, The Hain Celestial Group and Entergy
For Immediate Release
Chicago, IL – April 15, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Meritage Homes Corp. (MTH - Free Report) , Sarepta Therapeutics, Inc. (SRPT - Free Report) , The Clorox Company (CLX - Free Report) , The Hain Celestial Group, Inc. (HAIN - Free Report) and Entergy Corp. (ETR - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
5 Stocks to Win Big This Brutal Q1 Earnings Season
First-quarter corporate profits will certainly show contraction as the economy is hammered by the coronavirus outbreak and the subsequent shutdowns. The quarter will most likely be a complete washout for many companies, particularly retailers and restaurants.
The pandemic has also brought Airline, Hospitality and Auto industries to a grinding halt. These segments have been hurt by the massive drop in discretionary spending.
Overall, business activities in the United States contracted in March, slipping to a record low as the outbreak dampened activity in the manufacturing and service sectors. The virus, in particular, has crippled the manufacturing sector primarily due to the stay-at-home directives in several parts of the country. Coronavirus-induced supply chain disruptions and social distancing measures impacted factory activities.
By the way, earnings estimates for the first quarter have started to move down as the pandemic has halted economic growth and led market pundits to forecast a recession this year. Several oil bigwigs including Exxon Mobil and Chevron have slashed estimates. After all, the pandemic has hit oil demand and led to oversupply issues.
Automakers General Motors and Ford, and aerospace giant Boeing too trimmed estimates. In fact, Bank of America sees first-quarter earnings decline of 13% year over year. It also expects year-on-year earnings decline in all four quarters of this year, marking the first recession since 2015-16.
Broader bank earnings are going to take a hit as well. A low interest rate environment does cut into net interest income for banks. At the same time, rising unemployment is expected to result in increased loan losses, something that will weigh on banks’ earnings. Companies had to lay off workers in the wake of the rapid spread of COVID-19 and its impact on businesses (read more: 4 Winning Bank Stocks for Coronavirus-Marred Q1 Earnings).
For the first quarter as a whole, total earnings for S&P 500 companies are expected to drop 9% from the same period last year. Revenues, in the meanwhile, are likely to rise only 1.6% (read more: What to Expect from Big Bank Earnings Amid the Coronavirus?).
On the brighter side, there are certain sectors which might see earnings growth. Such sectors with positive earnings growth in the first quarter includes Construction (+4.2%), Medical (+0.9%), Consumer Staples (+0.6%) and Utilities (+1.9%). The virus scare has fueled demand for U.S. debt, which in turn pushed Treasury yields to new lows. Mortgage rates are most likely to go down as they generally follow the direction of the yield on the 10-year Treasury note in the United States. And lower mortgage rates will certainly boost homebuying.
Medical stocks have also defied the turbulent times. And it’s mostly because these companies are trying to develop a treatment for coronavirus, which helped garner impressive gains over the last couple of weeks. And should these clinical tests prove successful, such stocks will scale north.
And as the market is plagued with uncertainty, defensive stocks have performed relatively better. This is because such stocks are generally non-cyclical, or companies whose business performance and sales are not highly correlated with activities in the larger market. Their products are in constant demand irrespective of market volatility and such companies include names from the utilities and consumer staples sectors.
Utilities are deemed defensive stocks as electricity, gas and water are essentials. Food, beverage and tobacco companies are true defensive plays as demand for such staple stocks remains unaffected by economic downturns.
5 Stocks to Gain Heading Into Q1 Earnings
It will be prudent to consider solid companies from the aforesaid winning sectors, which are expected to report an uptick in first-quarter earnings. These stocks have a positive Earnings ESP. This is our proprietary methodology for determining stocks that have the best chance to surprise with their next earnings announcement. It provides the percentage difference between the Most Accurate Estimate and the Zacks Consensus Estimate.
Meritage Homes Corp. is one of the leading designers and builders of single-family homes. The stock has a Zacks Rank #3 (Hold). The company is expected to report earnings results for the quarter ending March on Apr 28. Meritage Homes has an Earnings ESP of +4.70%. The company’s expected earnings growth rate for the current quarter and year is 25.2% and 6.4%, respectively.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The stock has a Zacks Rank #3. The company is expected to report earnings results for the quarter ending March on May 13. Sarepta Therapeutics has an Earnings ESP of +20.20%. The company’s expected earnings growth rate for the current quarter is 48.1%.
The Clorox Company manufactures and markets consumer and professional products. The stock has a Zacks Rank #1 (Strong Buy). The company is expected to report earnings results for the quarter ending March on May 1. Clorox has an Earnings ESP of +1.81%. The company’s expected earnings growth rate for the current and next year is 1.7% and 5.4%, respectively. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Hain Celestial Group, Inc. manufactures, markets, distributes, and sells organic and natural products. The stock has a Zacks Rank #1. The company is expected to report earnings results for the quarter ending March on May 14. Hain Celestial has an Earnings ESP of +9.24%. The company’s expected earnings growth rate for the current quarter and year is 14.3% and 10.6%, respectively.
Entergy Corp. engages in the production and distribution of electricity in the United States. The stock has a Zacks Rank #3. The company is expected to report earnings results for the quarter ending March on May 6. Entergy has an Earnings ESP of +5.69%. The company’s expected earnings growth rate for the current and next year is 2.8% and 7.9%, respectively.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.